Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.55)
# 3,910
Out of 4,858 analysts
55
Total ratings
26.53%
Success rate
-32.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $3.70 | +197.70% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $7.30 | +324.66% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.86 | +921.51% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $4.50 | +366.67% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $2.45 | +104.50% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.28 | +1,154.90% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $0.34 | +2,807.82% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $13.14 | +90.26% | 2 | May 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $1.13 | +17,599.12% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.14 | +514.04% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.27 | +690.51% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $8.50 | +605.88% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.32 | +1,769.16% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.67 | +114.15% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.66 | +36,530.04% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $7.47 | +2,336.41% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.40 | +19,900.00% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.60 | +669.23% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.62 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.88 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.18 | +408.47% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.85 | +137.29% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $8.49 | +123,574.91% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.80 | +1,221.43% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $9.55 | +109.42% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $518.60 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $68.83 | +29.30% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $124.16 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $0.74 | +135,071.67% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.13 | +15,674.65% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.38 | +433.33% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $3.70
Upside: +197.70%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $7.30
Upside: +324.66%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.86
Upside: +921.51%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $4.50
Upside: +366.67%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $2.45
Upside: +104.50%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.28
Upside: +1,154.90%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $0.34
Upside: +2,807.82%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $13.14
Upside: +90.26%
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $1.13
Upside: +17,599.12%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.14
Upside: +514.04%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.27
Upside: +690.51%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $8.50
Upside: +605.88%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.32
Upside: +1,769.16%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.67
Upside: +114.15%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.66
Upside: +36,530.04%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $7.47
Upside: +2,336.41%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.40
Upside: +19,900.00%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $2.60
Upside: +669.23%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.62
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.88
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.18
Upside: +408.47%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.85
Upside: +137.29%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $8.49
Upside: +123,574.91%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.80
Upside: +1,221.43%
Nov 8, 2021
Upgrades: Buy
Price Target: $20
Current: $9.55
Upside: +109.42%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $518.60
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $68.83
Upside: +29.30%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $124.16
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $0.74
Upside: +135,071.67%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.13
Upside: +15,674.65%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.38
Upside: +433.33%